Evaluation of the effects and plasma concentration of the potent platelet inhibitor ticagrelor, after crushed and non-crushed intake, after semi-urgent coronary bypass and in patients after cardiac arrest.
Phase of Trial: Phase IV
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Ticagrelor (Primary)
- Indications Angina pectoris; Myocardial infarction
- Focus Pharmacokinetics; Therapeutic Use
- 16 Jan 2015 Planned End Date changed from 28 Nov 2016 to 1 Jan 2017, according to ClinicalTrials.gov record.
- 16 Jan 2015 Planned primary completion date changed to 1 Jul 2016, according to ClinicalTrials.gov record.
- 16 Jan 2015 Planned initiation date changed to 1 Jan 2015, according to ClinicalTrials.gov record.